A recent study suggests that patients who discontinue blockbuster GLP-1 drugs like Wegovy and Mounjaro may regain reduced body mass far faster than those who stop conventional diet and exercise programs.
Research printed in a leading medical journal shows that while obese individuals can lose substantial amounts of their body weight while using the jabs, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation.
"People purchasing such medications should be informed of the potential of rapid weight regain when the medication is stopped," warns lead investigator Dr. Susan Jebb.
This pace of recovery implies a reversion to original weight within about a year and a half.
Analyzing Therapies
The study, which examined 37 of trials involving thousands of patients, contrasted the effects of the injectable medications with other pills.
Scientists note that individuals who shed pounds through diet and exercise generally have a slower creep back—approximately 100 grams monthly—after stopping.
Understanding the Quick Regain
Experts believe the mode of action of the jabs accounts for the accelerated weight return.
The injections copy a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Long-term administration of the hormone concentrations several times higher than normal might result in the system to produce less of its own natural GLP-1, and could lessen sensitivity to its effects," noted Dr. Adam Collins, a dietetics expert.
"Discontinuation of this GLP-1 'fix' means appetite is unsuppressed, making binge eating a significant risk."
A Lifelong Disease?
Medical guidelines advise the jabs for individuals with obesity-related health risks, accompanied by recommended lifestyle changes.
Many experts contend that, due to the likelihood of weight regain, the treatment is often life-long.
This view is reinforced by pharmaceutical companies, who note that the results "underscore the persistent nature of obesity," comparing it to managing conditions like high blood pressure.
User Accounts
Individuals who have come off the jabs explain a intense resurgence of hunger.
"It felt as if a trigger flipping and I was suddenly ravenous," said an individual.
This challenge is worsened if patients have not adopted lasting dietary or behavioural changes during therapy.
Widespread Interest
Figures indicate that millions of adults in the UK have tried weight-loss jabs in the past year, with interest remaining high.
- Adoption is more common among females than males.
- The 40s and 50s demographic shows the greatest level of interest.
- Many access the medications through private healthcare rather than the NHS.
Finally, clinicians stress that while the jabs are powerful agents for shedding pounds, they are not a standalone cure and lasting health benefits likely depends on integrated lifestyle changes.
